Φορτώνει......
Optimal biological dose: a systematic review in cancer phase I clinical trials
BACKGROUND: Classical phase 1 dose-finding designs based on a single toxicity endpoint to assess the maximum tolerated dose were initially developed in the context of cytotoxic drugs. With the emergence of molecular targeted agents and immunotherapies, the concept of optimal biological dose (OBD) wa...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | BMC Cancer |
|---|---|
| Κύριοι συγγραφείς: | , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BioMed Central
2021
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7805102/ https://ncbi.nlm.nih.gov/pubmed/33441097 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-07782-z |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|